TD Cowen maintains IQVIA Holdings at Buy, raises price target to $307 from $288
TD Cowen reaffirmed its Buy rating for IQVIA Holdings and increased its price target to $307 from $288. The new target suggests a 10% upside from the last close of $279.04. Recent analyst notes have set price targets for the company between $303 and $346.
How this was made
The 30-second read
Why it matters
The upgrade may attract new buying, supporting short-term price gains.
Market read
A fresh analyst price target can move the stock, offering a short‑term trading edge.
What to watch
Potential regulatory or reimbursement risks not addressed in the note.
Background
TD Cowen maintains a Buy rating on IQVIA and adjusts its valuation upward.
Ticker impact
TD Cowen raised its price target on IQVIA Holdings to $307 from $288, a 6.6% increase.
likely upward pressure as investors price in the higher target
The new target implies a 10% upside from the recent close, prompting buying interest.
Market effects
May lift sentiment in the healthcare data and analytics sector.
Limited to US equities; no broader regional effect.
Minor global impact, confined to IQVIA and peers.
Counterpoint
The target raise could be premature if upcoming earnings miss expectations.
Key entities
- analystTD Cowen
Equity research firm issuing the rating and target.
- companyIQVIA Holdings
Provider of health information technology and clinical research services.
